News.
Stay informed with the latest articles from the Sharewise team. From in-depth stock spotlights to market updates and thought leadership, our news section helps you navigate opportunities across the ASX and global markets.
Jackson Hole 2025 recap: Fed Chair Powell signals a patient stance on inflation as demographics, productivity and policy divergence shape markets.
This week's Stock Spotlight is ASX-listed Mirvac Group. About Mirvac Group. Founded in 1972, Mirvac is an Australian Securities Exchange (ASX) listed company, with an integrated asset creation and curation capability. We own and manage assets across office, retail, industrial and the living sectors in our investment portfolio, with approximately $22 billion of assets under management. Our development activities span commercial and mixed-use and residential, with a development pipeline of approximately $29 billion. We focus on delivering high-quality, innovative and sustainable real estate for our customers, while driving long-term value for our securityholders. Source: Yahoo Finance Key Stats
Get the latest Commowealth Bank Of Australia (ASX:CBA) stock updates, technical analysis, forecasts & investment insights. See if CBA is the right stock for you.
About Telix Pharmaceuticals Ltd Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is in a Phase 3 clinical trial in patients with advanced prostate cancer. The company develops TLX250, an rADC for treating advanced metastatic kidney cancer; TLX101, a systemic therapy for the treatment of glioblastoma; TLX66, a product candidate for bone marrow conditioning for hematopoietic stem cell transplant conditioning; and Illuccix and Gozellix for the treatment of prostate cancer. The company is also developing TLX592, a prostate cancer therapy candidate for targeted alpha therapy based on its proprietary RADmAb-engineered antibody technology; TLX252 for the treatment of patients with advanced metastatic kidney cancer; TLX400, a bladder fibroblast activation protein for treating various tumors; TLX102, a large amino acid transporter-targeting small molecule-based alpha therapy candidate for the treatment of glioblastoma and multiple myeloma; TLX300 for treating soft tissue sarcoma; and TLX090, a bone-seeking agent for bone metastases and pain palliation. In addition, it is developing TLX250-CDx, a positron emission tomography (PET) diagnostic imaging agent for the characterization of renal masses as clear cell renal cell carcinoma; TLX101-CDx, a PET diagnostic agent to image cancerous lesions in the brain; and TLX66-CDx, a cluster of differentiation 66 imaging agent for osteomyelitis (bone infection). It operates in Australia, Belgium, Canada, the United Kingdom, the United States, and internationally. The company was founded in 2015 and is headquartered in North Melbourne, Australia. Key Stats
Subscribe to our Newsletter.
Want our latest stock spotlights and market insights delivered straight to your inbox? Subscribe to our newsletter for updates on new articles, webinars, and events.
Stock Spotlights
Highlighting different ASX, US and other global stocks.
This week's Stock Spotlight is ASX-listed Mirvac Group. About Mirvac Group. Founded in 1972, Mirvac is an Australian Securities Exchange (ASX) listed company, with an integrated asset creation and curation capability. We own and manage assets across office, retail, industrial and the living sectors in our investment portfolio, with approximately $22 billion of assets under management. Our development activities span commercial and mixed-use and residential, with a development pipeline of approximately $29 billion. We focus on delivering high-quality, innovative and sustainable real estate for our customers, while driving long-term value for our securityholders. Source: Yahoo Finance Key Stats
Get the latest Commowealth Bank Of Australia (ASX:CBA) stock updates, technical analysis, forecasts & investment insights. See if CBA is the right stock for you.
About Telix Pharmaceuticals Ltd Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is in a Phase 3 clinical trial in patients with advanced prostate cancer. The company develops TLX250, an rADC for treating advanced metastatic kidney cancer; TLX101, a systemic therapy for the treatment of glioblastoma; TLX66, a product candidate for bone marrow conditioning for hematopoietic stem cell transplant conditioning; and Illuccix and Gozellix for the treatment of prostate cancer. The company is also developing TLX592, a prostate cancer therapy candidate for targeted alpha therapy based on its proprietary RADmAb-engineered antibody technology; TLX252 for the treatment of patients with advanced metastatic kidney cancer; TLX400, a bladder fibroblast activation protein for treating various tumors; TLX102, a large amino acid transporter-targeting small molecule-based alpha therapy candidate for the treatment of glioblastoma and multiple myeloma; TLX300 for treating soft tissue sarcoma; and TLX090, a bone-seeking agent for bone metastases and pain palliation. In addition, it is developing TLX250-CDx, a positron emission tomography (PET) diagnostic imaging agent for the characterization of renal masses as clear cell renal cell carcinoma; TLX101-CDx, a PET diagnostic agent to image cancerous lesions in the brain; and TLX66-CDx, a cluster of differentiation 66 imaging agent for osteomyelitis (bone infection). It operates in Australia, Belgium, Canada, the United Kingdom, the United States, and internationally. The company was founded in 2015 and is headquartered in North Melbourne, Australia. Key Stats
About Vicinity Centres Vicinity Centres (Vicinity or the Group) is one of Australia leading retail property groups with a fully integrated asset management platform, and $24 billion in retail assets under management across 52 shopping centres, making it the second largest listed manager of Australian retail property. The Group has a Direct Portfolio with interests in 51 shopping centres (including the DFO Brisbane business) and manages 24 assets on behalf of Strategic Partners. Vicinity is listed on the Australian Securities Exchange (ASX) under the code VCX and has circa 21,000 securityholders. Vicinity also has European medium term notes listed on the ASX under the code VCD. Key Stats
This week's Stock Spotlight is ASX-listed Arena REIT . About Arena REIT. Arena REIT is an ASX200 listed property group that develops, owns and manages social infrastructure properties across Australia. Our current portfolio of social infrastructure properties is leased to a diversified tenant base in the growing early learning and healthcare sectors. Source: Yahoo Finance Key Stats
About Charter Hall Social Infrastructure REIT Charter Hall Retail REIT is the leading owner of property for convenience retailers. Charter Hall Retail REIT is managed by Charter Hall Group (ASX: CHC). Charter Hall is one of Australia's leading fully integrated property investment and funds management groups. We use our expertise to access, deploy, manage and invest equity to create value and generate superior returns for our investor customers. We've curated a diverse portfolio of high-quality properties across our core sectors Office, Industrial & Logistics, Retail and Social Infrastructure. With partnerships and financial discipline at the heart of our approach, we create and invest in places that support our customers, people and communities to grow. Key Stats
Get the latest CSL Limited (ASX: CSL) stock updates, technical analysis, expert forecasts & investment insights. See if CSL is the right stock for you!
About James Hardie Industries Plc James Hardie Industries plc engages in the manufacture and sale of fiber cement, fiber gypsum, and cement bonded boards in the United States, Australia, Europe, and New Zealand. It operates in three segments: North America Fiber Cement, Asia Pacific Fiber Cement, and Europe Building Products. The company offers fiber cement interior linings, exterior siding products, and related accessories. Its fiber cement products are used for a range of external applications, including siding, cladding, trim, soffit, as well as internal applications such as walls, floors, and ceilings. The company also provides fiber gypsum and cement-bonded boards for interior applications, such as dry lining walls, walls in timber frame buildings, and flooring solutions. Its cement-bonded boards are used in exterior and industrial applications, as well as for fire protection. The company offers its products under the HardieTM brand, such as Hardie Plank, Hardie Panel, Hardie Trim, Hardie Backer, Hardie Artisan Siding, and HardieTM Architectural Collection brands, as well as the fermacell and AESTUVER brands. James Hardie Industries plc was founded in 1888 and is headquartered in Dublin, Ireland. Key Stats
Insights
In-depth commentary and analysis covering market outlooks, investment themes, and global trends.
Jackson Hole 2025 recap: Fed Chair Powell signals a patient stance on inflation as demographics, productivity and policy divergence shape markets.
When navigating during uncertain or volatile market conditions, investment portfolios should prioritise caution and flexibility. Holding a healthy cash position is essential as the saying goes ‘cash is king’. Certainly, during frequently shifting market sentiment, facilitating readiness to act when genuine opportunities arise is crucial. For new investments, confirmation of trend reversals or stability before entering positions is a strategy to avoid catching falling knives. For new investments, waiting for confirmation of trend reversals or market stability before entering positions is a prudent strategy to avoid catching falling knives. Implementing a dollar-cost averaging (DCA) approach enables positions to be built gradually, helping to mitigate the effects of market volatility and emotional decision-making. A balanced investment strategy assists in managing risk while positioning a portfolio to capitalise on potential rebounds.
Gold is once again making headlines in 2025 as its value has risen to unprecedented levels since the start of the year. It recently surpassed $3000 USD per ounce as investors flock to its time tested safe-haven appeal. This isn’t just another bull run, a powerful combination of geopolitical shifts, inflation fears, and changing market dynamics is fuelling what could be gold's most significant rally in decades.
When US stocks plummeted by almost 4%, with NVDA down by 7% and Apple down by 4%, Bitcoin dropped by almost 15%. Why did this happen?
The global financial landscape has been rocked by escalating trade tensions, with US policies under President Donald Trump causing significant market fluctuations. Investors worldwide are grappling with uncertainty as tariff threats, economic instability, and geopolitical risks weigh heavily on equity markets. This article explores the effects of these factors on both the Australian Securities Exchange (ASX) and US equity markets.
Self-Managed Super Funds (SMSFs) are a powerful way for Australians to take control of their retirement savings. But to achieve long-term growth and financial security, SMSF investors need the right strategy—one that includes both Australian and US shares. At Sharewise, we specialise in helping SMSF investors navigate both ASX and US markets with expert research, low-cost execution, and tax-efficient investment strategies.
As the world’s financial markets become more interconnected, more Australian investors are looking beyond the ASX to build diversified portfolios that include exposure to major global markets. One of the most popular ways to tap into the growth and resilience of the US economy is through the S&P 500, a leading benchmark of American equities. This article explores the S&P 500, its benefits and risks, and how our US share advisory service at Sharewise can help Australians navigate this essential market. What is the S&P 500? The S&P 500, short for Standard & Poor’s 500, is a stock market index that represents the 500 largest publicly traded companies in the United States. Managed by Standard & Poor’s, the index reflects around 80% of the total US stock market capitalisation and covers companies across 11 sectors. The S&P 500 serves as a key barometer of the US economy’s performance, tracking some of the world’s most recognised and innovative companies, such as Apple, Microsoft, Amazon, and Google. The S&P 500 is a market-capitalisation-weighted index, meaning companies with higher market values have a greater influence on the index’s performance. This structure ensures that the S&P 500 is responsive to the successes of the largest and most impactful companies, while the diverse sector coverage captures a broad view of the US economy’s overall health and trends.
Since CEO Simon Crowther took the helm at childrens’ wearables company Spacetalk (ASX:SPA), the company has undergone a dramatic turnaround. In its latest quarterly announcement, for Q4FY24, Spacetalk revealed that it has achieved positive cash flow of $0.85 million (Q4FY23: negative -$1.5million) and positive free cash flow of $0.37 million (Q4FY23: negative -$2.24 million).
